Table 2.
The interaction between SOD2 Val16Ala and SEPP1 Ala234Thr SNPs and risk of all prostate cancer, non-aggressive prostate cancer and aggressive prostate cancer in the CAPS study.
| Controls | All prostate cancer | Non-aggressive prostate cancer | Aggressive prostate cancer | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | n | n | OR (95% CI)* | P | n | OR (95% CI)* | P | n | OR (95% CI)* | P |
| SEPP1 Codon 234 Ala/Ala | 816 | 1360 | 854 | 506 | ||||||
| SOD2 Val/Val | 224 | 286 | Referent | 1 | 189 | Referent | 1 | 97 | Referent | 1 |
| SOD2 Ala/Val + Ala/Ala | 592 | 1074 | 1.43 (1.17 to 1.76) | 0.0005 | 665 | 1.36 (1.09 to 1.71) | 0.0073 | 409 | 1.60 (1.22 to 2.09) | 0.0007 |
| SEPP1 Codon 234 Ala/Thr + Thr/Thr | 638 | 1009 | 631 | 378 | ||||||
| SOD2 Val/Val | 161 | 246 | Referent | 1 | 147 | Referent | 1 | 99 | Referent | 1 |
| SOD2 Ala/Val + Ala/Ala | 477 | 763 | 1.06 (0.84 to 1.34) | 0.62 | 484 | 1.14 (0.87 to 1.48) | 0.35 | 279 | 0.95 (0.71 to 1.28) | 0.75 |
| P for interaction | 0.051 | 0.278 | 0.012 | |||||||
*
odds ratio adjusted for age and geographical location, 95% confidence interval
n = Number of subjects